M2-PK: detecting colonic polyps and cancer

March 06, 2015

Early detection of colonic polyps and their prompt removal is a fundamental goal of colorectal cancer screening and prevention. Results of a new multicentre study demonstrate sensitivity for the ScheBo M2-PK Quick test of 92.8% for bowel cancer and 69.4% for polyps. The ScheBo M2-PK Quick test detected twice as many bowel cancer cases and nearly six times the number of polyps compared with an immunological faecal occult blood test (FIT) also included in the study.

The ScheBo M2-PK Quick rapid test detects M2-PK, an innovative metabolic biomarker that is elevated in colorectal cancer, in faeces and is extremely easy to perform. The patient being screened simply collects a few grams from a single sample of formed stool, using the hygienic collection device provided. Laboratory results are obtained in just five minutes following completion of the simple stool extraction procedure using a ScheBo Quick-Prep device prefilled with buffer, which is supplied in the kit.
[email protected]

Sponsors

M2-PK: detecting colonic polyps and cancer

Other News

New anti-GFP antibodies from Jackson ImmunoResearch

Revvity expands work with Genomics England

3D multimodal imaging from CrestOptics and Tomocube

Owkin and Proscia partner for CRC pre-screening

New nasal vaccine shows promise in curbing whooping cough spread

Biofidelity launches Aspyre Lung reagents

Linkam launches CMS196V4 stage for cryo-CLEM microscopy

Abbott opens state-of-the-art manufacturing facility in Kilkenny, Ireland

Lunit and AstraZeneca partner for AI-powered digital pathology cancer tools

Latest Issues

Featured Supplier

Upcoming Events

Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo

11th Digital Pathology & AI Congress: Europe

Microbiology Society Annual Conference 2025

BSMT Annual Microbiology Conference

Ghent Pathology 2025